Phase III APeX-2 and APeX-S trials of BCX 7353 show improvements in hereditary angioedema.- BioCryst Pharma
BioCryst Pharmaceuticals announced new data from the phase III APeX-2 and APeX-S clinical trials, which showed that hereditary angioedema (HAE) patients taking oral, once-daily BCX 7353 (berotralstat) experienced… read more.